# US 12,006,362 B2 · Anti-interleukin-6 receptor antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,006,362 B2
- Document ID: US12006362B2
- Status: Granted
- Kind: B2
- Application number: 17/519,069
- Filed: 2021-11-04
- Published: 2022-06-23
- Granted: 2024-06-11
- Earliest claimed: 2016-05-27
- Assignees: Deijing Vdjbio Co., Ltd.
- Applicants: Beijing VDJBio Co., Ltd.
- Inventors: Ziqiang Li
- Web page: https://patentgrep.com/patent/US12006362B2

## CPC

- C07K 16/248: {IL-6}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

In some aspects, the present disclosure provides antibodies with high target affinities, as well as compositions comprising the same, and methods of using the same. In some embodiments, antibodies against an IL6 receptor are provided.

## Claims

### Claim 1

A method of neutralizing Interleukin-6 receptor (IL-6R) in a subject, the method comprising administering an effective amount of anti-IL-6R antibody to the subject,
wherein the antibody comprises a heavy chain and a light chain,
wherein the heavy chain comprises an amino acid sequence with 95% or greater sequence identity to SEQ ID NO. 28, and wherein the amino acid sequence of the heavy chain comprises: F at position 51, M at position 57, and I at position 103; and
wherein the light chain comprises an amino acid sequence with 95% or greater sequence identity to SEQ ID NO. 4, and wherein the amino acid sequence of the light chain comprises G at position 89 and Rat position 93.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is suffering from a disease or condition that is selected from the group consisting of: acute disseminated encephalomyelitis (ADEM), Addison's disease, antiphospholipid antibody syndrome (APS), aplastic anemia, autoimmune hepatitis, coeliac disease, Crohn's disease, Diabetes mellitus (type 1), Goodpasture's syndrome, Graves' disease, Guillain-Barré syndrome (GBS), Hashimoto's disease, multiple sclerosis, myasthenia gravis, opsoclonus myoclonus syndrome (OMS), optic neuritis, Ord's thyroiditis, pemphigus, polyarthritis, primary biliary cirrhosis, psoriasis, rheumatoid arthritis, inflammatory bowel disease (IBD), juvenile idiopathic arthritis (JIA), psoriatic arthritis, systemic lupus erythematosus (SLE), asthma, Reiter's syndrome, Takayasu's arteritis, temporal arteritis, warm autoimmune hemolytic anemia, Wegener's granulomatosis, alopecia universalis, Chagas' disease, chronic fatigue syndrome, dysautonomia, endometriosis, hidradenitis suppurativa, interstitial cystitis, neuromyotonia, sarcoidosis, scleroderma, ulcerative colitis, vitiligo, vulvodynia, infection, endotoxic shock associated with infection, arthritis, pelvic inflammatory disease, Alzheimer's Disease, irritable bowel syndrome, ankylosing spondylitis, dermatomyositis, uveitis, Peyronie's Disease, gallbladder disease, Pilonidal disease, peritonitis, vasculitis, surgical adhesions, stroke, lyme arthritis, meningoencephalitis, pancreatitis, trauma from surgery, graft-versus-host disease, transplant rejection, heart disease, bone resorption, burns, myocardial infarction, Paget's disease, osteoporosis, sepsis, liver fibrosis, lung fibrosis, periodontitis, hypochlorhydria, renal cell carcinoma, liver cancer, multiple myeloma, prostatic cancer, bladder cancer, pancreatic cancer, Castleman's Disease, and B-cell malignancies.

### Claim 3 (depends on 2)

The method of claim 2, wherein the disease or condition is Castleman's Disease.

### Claim 4 (depends on 1)

The method of claim 1, wherein the heavy chain comprises the amino acid sequence with 97% or greater sequence identity to SEQ ID NO. 28.

### Claim 5 (depends on 4)

The method of claim 4, wherein the light chain comprises the amino acid sequence with 97% or greater sequence identity to SEQ ID NO. 4.

### Claim 6 (depends on 4)

The method of claim 4, wherein the light chain comprises the amino acid sequence with 99% or greater sequence identity to SEQ ID NO. 4.

### Claim 7 (depends on 4)

The method of claim 4, wherein the light chain comprises the amino acid sequence of SEQ ID NO. 4.

### Claim 8 (depends on 1)

The method of claim 1, wherein the heavy chain comprises the amino acid sequence with 99% or greater sequence identity to SEQ ID NO. 28.

### Claim 9 (depends on 8)

The method of claim 8, wherein the light chain comprises the amino acid sequence with 97% or greater sequence identity to SEQ ID NO. 4.

### Claim 10 (depends on 8)

The method of claim 8, wherein the light chain comprises the amino acid sequence with 99% or greater sequence identity to SEQ ID NO. 4.

### Claim 11 (depends on 8)

The method of claim 8, wherein the light chain comprises the amino acid sequence of SEQ ID NO. 4.

### Claim 12 (depends on 1)

The method of claim 1, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO. 28.

### Claim 13 (depends on 12)

The method of claim 12, wherein the light chain comprises the amino acid sequence with 96% or greater sequence identity to SEQ ID NO. 4.

### Claim 14 (depends on 12)

The method of claim 12, wherein the light chain comprises the amino acid sequence with 97% or greater sequence identity to SEQ ID NO. 4.

### Claim 15 (depends on 12)

The method of claim 12, wherein the light chain comprises the amino acid sequence with 98% or greater sequence identity to SEQ ID NO. 4.

### Claim 16 (depends on 12)

The method of claim 12, wherein the light chain comprises the amino acid sequence with 99% or greater sequence identity to SEQ ID NO. 4.

### Claim 17 (depends on 12)

The method of claim 12, wherein the light chain comprises the amino acid sequence of SEQ ID NO. 4.

### Claim 18 (depends on 1)

The method of claim 1, wherein the antibody is a monoclonal antibody.

### Claim 19 (depends on 1)

The method of claim 1, wherein the light chain comprises the amino acid sequence of SEQ ID NO. 4.

### Claim 20 (depends on 2)

The method of claim 2, wherein the disease or condition is rheumatoid arthritis.

### Claim 21 (depends on 17)

The method of claim 17, wherein the subject is suffering from Castleman's Disease.

### Claim 22 (depends on 17)

The method of claim 17, wherein the subject is suffering from rheumatoid arthritis.